Tesamorelin: the FDA-approved GHRH analogue guide

Tesamorelin peptide is the only growth-hormone-releasing peptide with FDA approval (also commonly searched as "tesamorlin"). Marketed as Egrifta, the tesamorelin peptide is approved for HIV-associated lipodystrophy (excess abdominal fat accumulation in HIV patients on antiretroviral therapy). Outside that indication, it's used in research-use GH-axis protocols as a more potent, and more regulated, alternative to CJC-1295.

What Tesamorelin is#

Tesamorelin is a synthetic 44-amino-acid analogue of native growth hormone-releasing hormone (GHRH). Native GHRH is rapidly degraded in plasma; Tesamorelin is modified with a trans-3-hexenoic acid tail that dramatically extends its half-life (to ~26–38 minutes versus a few minutes for native GHRH). That extension is enough to sustain a meaningful therapeutic GHRH signal from a once-daily subcutaneous dose.

Mechanistically, Tesamorelin activates pituitary GHRH receptors, the same target as CJC-1295, Sermorelin, and other GHRH analogues. Receptor activation triggers endogenous GH release, which drives IGF-1 elevation over subsequent hours.

What distinguishes Tesamorelin is the selectivity for visceral fat. In the pivotal Falutz et al. trial (NEJM, 2007), Tesamorelin has been shown to reduce visceral adipose tissue (the deep abdominal fat associated with metabolic disease) by 15–20% over 26 weeks, with minimal effect on subcutaneous fat. This pattern, visceral-selective fat loss, is the clinical signature that differentiates Tesamorelin from other GH-axis peptides.

FDA approval and the HIV indication#

Tesamorelin was approved by the FDA in 2010 under the brand name Egrifta (later Egrifta SV). The indication is HIV-associated lipodystrophy: in HIV patients on antiretroviral therapy, distinctive patterns of body-fat redistribution occur, often with marked accumulation of visceral fat that carries cardiovascular and metabolic risk. Tesamorelin is approved specifically to reduce that visceral fat accumulation.

This is a relatively narrow approved indication. Tesamorelin is not approved for general weight loss, general GH-axis use, or age-related body-composition changes in non-HIV populations. Outside the approved indication, Tesamorelin is used off-label or for research purposes, the same regulatory status as CJC-1295 and Ipamorelin for those use cases.

In Norway, Tesamorelin/Egrifta is authorised by DMP under its HIV-lipodystrophy indication.

Dosing#

Tesamorelin dosage in the published evidence base splits cleanly between the FDA-approved indication and research-use protocols. The tesamorelin dosage in approved HIV-lipodystrophy trials sits at 2 mg once daily; research-use protocols sometimes anchor lower at 1 mg for general GH-axis effects.

Approved dose (HIV-associated lipodystrophy):

• Dose: 2 mg subcutaneously once daily
• Timing: evening, ideally before bed
• Duration: typically 6–12 months; continued use assessed against ongoing clinical benefit

Research-use dosing (for general GH-axis effects):

• Dose: 1–2 mg subcutaneously once daily
• Cycle length: 8–12 weeks on, 4 weeks off

Reconstitution: a typical vial contains 5 mg of Tesamorelin lyophilised with mannitol. Reconstitution with 2 mL of bacteriostatic water gives 2.5 mg/mL. A 2 mg dose = 0.8 mL = 80 syringe units. The peptide calculator handles any vial size and target dose.

Tesamorelin is sensitive to shear stress. Vigorous shaking during reconstitution can inactivate the peptide. Use gentle swirling and a 30–60 second rest.

Expected effects#

Tesamorelin's expected effects track the GH-axis activation pattern, with specific emphasis on body composition:

Short-term (weeks 1–4): improved sleep quality, mild transient water retention, gradual IGF-1 elevation

Medium-term (weeks 4–16): noticeable reduction in visceral adipose tissue, minor changes in subcutaneous fat, modest lean-mass preservation or gain

Long-term (16+ weeks on therapy): sustained VAT reduction, improved lipid profile (typically lower triglycerides, improved HDL), and research suggests improved insulin sensitivity in most users when bloodwork is monitored across the cycle

IGF-1 monitoring is important. Target is to keep IGF-1 in the upper half of the age-adjusted reference range without exceeding it. Klarovel's questionnaire integrates bloodwork scheduling with the protocol.

Side effects#

Tesamorelin's side-effect profile is well characterised from the FDA approval trials:

• Injection-site reactions (~25%, mild to moderate)
• Joint pain and muscle pain (~10–15%)
• Transient water retention in the first 1–3 weeks
• Mild carpal tunnel symptoms (fluid retention in tissues around the median nerve)
• Elevated fasting glucose (less pronounced than with MK-677; worth monitoring)

Less common but more serious:

• Hypersensitivity reactions (rash, flushing)
• Mannitol hypersensitivity (contraindication for known sensitivity)
• Pituitary hormone changes

Tesamorelin vs CJC-1295#

Both are GHRH analogues. The differences that matter:

	Tesamorelin	CJC-1295 (no DAC)
Half-life	~26–38 min	~30 min
FDA approval	Yes (Egrifta, HIV-lipodystrophy)	No
Structural modification	Trans-3-hexenoic acid tail	Amino-acid substitution
Approved dose	2 mg daily	,
Research dose	1–2 mg daily	100 mcg per injection, 1–3× daily
Cost per mcg	Typically higher	Typically lower

For general GH-axis effects, CJC-1295 (no DAC) is the more cost-efficient choice with a longer research-use track record. For users who specifically want the visceral-fat-reduction profile documented in FDA approval trials, Tesamorelin has the clinical evidence edge. For users who want an approved medicine, Tesamorelin is the only option in the GH-axis peptide class.

Practical framework#

Three questions filter the Tesamorelin decision:

1. Is the goal visceral fat reduction specifically? Tesamorelin's FDA approval data supports this indication. For general body-composition goals, the difference from CJC-1295 is minor.
2. Is regulatory approval important? If the user's framework requires an FDA- or EMA-approved GH-axis peptide, Tesamorelin is the only option.
3. Is cost a factor? Tesamorelin (Egrifta) at approved dose is substantially more expensive per month than research-use CJC-1295 at equivalent effect. For cost-sensitive research protocols, CJC-1295 (no DAC) is typically the entry point.

For protocol planning, Klarovel's questionnaire handles screening. The peptide calculator handles dose math. The Ipamorelin guide covers the common GHRP pairing. For class-level mechanism, see the GLP-1 class explained (different class, but similar framing).

Tesamorelin is the GH-axis peptide with the strongest approval credentials and a specific, documented clinical use case. It is not the cheapest or the most versatile option in the class. For visceral-fat-focused protocols in users who want regulatory-approved pharmacology, it's the right choice. For general GH-axis support, the CJC-1295 + Ipamorelin stack covers most use cases at lower cost. To place Tesamorelin's GHRH-analogue mechanism in the wider context of how the system works, the GH axis explained maps the full GH-IGF-1 pathway.